Status:
COMPLETED
Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India
Lead Sponsor:
Pfizer
Conditions:
PLASMODIUM FALCIPARUM MALARIA
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This primary objective of this study is to assess whether the combination of Azithromycin with chloroquine is non-inferior to the combination of sulfadoxine-pyrimethamine plus chloroquine, when used t...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Females and males \>=18 years of age with uncomplicated, symptomatic malaria as indicated by the presence of both of the following: a.) Blood smears positive for Plasmodium falciparum asexual parasitemia between 1000 -100,000 parasites/uL; b.) Fever or history of fever ( \>=38.5C/101.2F rectal or tympanic; \>=37.5C/99.5F axillary or \>=38C/100.4F oral) within the prior 24 hours
- Serum glucose \>= 60 mg/dL (by fingerstick or peripheral blood collection)
- Positive rapid diagnostic test (Binax NOW ICT) positive for P. falciparum
- Women of childbearing potential must have a negative urine gonadotropin prior to entry into the study and must agree to use adequate contraception during the entire study
- EXCLUSION CRITERIA:
- Severe or complicated malaria including subjects with any of the following: a.) Impaired consciousness (e.g. obtundation, unarousable coma), seizures or abnormal neurologic exam suggestive of severe or complicated malaria; b.) Hemoglobinuria; c.) Jaundice; d.) Respiratory distress (respiratory rate \>=30/min); e.) Persistent vomiting; f.) Hematuria, as reported by the patient
- Pregnant or breast-feeding women
- History of allergy to or hypersensitivity to azithromycin or any macrolide, sulfonamides, pyrimethamine, or chloroquine
- Known or suspected folate deficiency
- Known history of blood dyscrasias (e.g., megaloblastic anemia, agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, neutropenia, hemolytic anemia)
- Known G-6PD deficiency
- History of epilepsy or psoriasis
- History of treatment with any antimalarial drug (chloroquine, quinine, mefloquine, Malarone, SP, artemisinin compounds) or antibacterial with known antimalarial activity (macrolides, doxycycline, clindamycin) within 2 weeks prior to enrollment into the study
- Known or suspected cardiovascular, hepatic or renal abnormality that in the opinion of the Investigator would place the subject at increased risk to participate in the study. The following findings are specific exclusions: a.) Serum creatinine \>2.0 x ULN; b.) ALT and/or AST \>3 x ULN
- Inability to swallow oral medication in tablet form
- Treatment with other investigational drugs within 30 days prior to enrollment into the study
- Alcohol and/or any other drug abuse
- Requirement to use medication during the study that might interfere with the evaluation of the study drug
- Specific systemic diseases or other medical conditions that would interfere with the evaluation of the therapeutic response or safety of the study drug
- Inability to comprehend and/or unwillingness to follow the study protocol
- Prior participation in this study
Exclusion
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2005
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT00074841
Start Date
September 1 2003
End Date
January 1 2005
Last Update
May 10 2011
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Dispur Guwahati, Assam, India, 781006
2
Pfizer Investigational Site
Bambolim, Gao, India, 403002
3
Pfizer Investigational Site
Nagpur, Maharashtra, India, 440 018
4
Pfizer Investigational Site
Parel Mumbai, Maharashtra, India, 400012